LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

Kodu・Aktsiate loetelu・Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Suletud

SektorTervishoid

19.53 0.41

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.34

Max

19.87

Põhinäitajad
By Trading Economics
Sissetulek	258M 216M
Müük	280M 459M
P/E Sektori keskmine	55.833 106.172
Aktsiakasum	1.67
Kasumimarginaal	47.04
Töötajad	705
EBITDA	258M 228M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+70.03% upside

Turustatistika
By TradingEconomics
Turukapital	-1.2B 2.5B
Eelmine avamishind	19.12
Eelmine sulgemishind	19.53

Apellis Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. nov 2025, 23:07 UTC

Market Talk

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

20. nov 2025, 22:22 UTC

Market Talk

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

20. nov 2025, 22:08 UTC

Market Talk

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

20. nov 2025, 21:57 UTC

Tulu

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

20. nov 2025, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

20. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20. nov 2025, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

20. nov 2025, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

20. nov 2025, 21:31 UTC

Tulu

Nvidia's Strong Results Show AI Fears Are Premature -- Update

20. nov 2025, 21:23 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20. nov 2025, 21:07 UTC

Tulu

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20. nov 2025, 21:06 UTC

Tulu

Webull 3Q Rev $156.9M >BULL

20. nov 2025, 21:06 UTC

Tulu

Webull 3Q EPS 7c >BULL

20. nov 2025, 21:05 UTC

Tulu

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

20. nov 2025, 21:04 UTC

Tulu

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

20. nov 2025, 21:04 UTC

Tulu

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

20. nov 2025, 21:04 UTC

Tulu

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

20. nov 2025, 21:00 UTC

Tulu

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

20. nov 2025, 21:00 UTC

Tulu

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 Rev $21B-$21.19B >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit 1Q Consumer Rev $894M

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 Guidance

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit 1Q Global Business Solutions Rev $3B

Võrdlus sarnastega

Hinnamuutus

Apellis Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

70.03% tõus

12 kuu keskmine prognoos

Keskmine 33.07 USD 70.03%

Kõrge 52 USD

Madal 18 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Apellis Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

16 ratings

Osta

Hoia

Müü

Põhineb 16 analüütiku instrumendi Apellis Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.